Medical Device News Magazine

11/14/24 - Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market - Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets. https://lnkd.in/eJWgVQ-e

11/6/24: Transforming Diabetes Care: Why CGM Hardware Must Evolve for the Type 2 Population | By Dr. Chris Dawson, Head of Biosensing Instrument Inc at TTP. He writes, "The landscape of diabetes management is transforming, as continuous glucose monitoring (CGM) devices expand beyond Type 1 diabetes and into a rapidly growing Type 2 market. Changes to regulatory approvals and insurance coverage driven by improved patient outcomes have opened the door for non-insulin-dependent Type 2 patients to access CGM. Device manufacturers now face a new frontier: designing CGM hardware that meets the unique needs of an increasingly diverse patient population. For CGMs to realize their full potential in Type 2 diabetes management, it’s critical to rethink hardware design to cater to this population’s distinct requirements, improving usability, flexibility, and the quality of care." Read what he has to say at https://lnkd.in/e9GECmu9

11/4/24: Jason Whiting Appointed CEO of Avation Medical - details at https://lnkd.in/eCi_ZkmC

11/4/24: Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation The Paradise Ultrasound Renal Denervation (uRDN) system becomes the first and only ultrasound-based renal denervation (RDN) therapy to be granted a distinct category and device code for incremental Outpatient Transitional Pass-through (TPT) payment by CMS, recognizing the differentiation of Paradise uRDN system in facilitating Medicare fee-for-service beneficiary access to new and innovative medical technologies. More at https://lnkd.in/e-T3bX4R

11/4/2: Boston Scientific Announces Agreement to Acquire Cortex. Cortex is a privately held medical technology company focused on the development of a diagnostic mapping solution which may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder affecting nearly 38 million people globally https://lnkd.in/ee-DSdmZ

11/4/24: FDA Grants R3 Vascular Inc. IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease https://lnkd.in/ezTB6bmk

Have you registered to attend #VEITHsymposium #VEITH24 https://lnkd.in/ewRXb-36

11/4/24: Holiday Stress & Heart Health: How AI-Powered Remote Cardiac Monitoring Redefines Cardiovascular Wellness During High-Stress Seasons | By Stuart Long, CEO, InfoBionic.Ai In this article, Stuart Long explores the critical connection between stress and heart health, and discuss how AI-powered remote cardiac monitoring can help high-risk individuals avoid preventable cardiac events, especially during the holiday season. Read on at https://lnkd.in/e9kWeEUJ

10/31/24: Jay Hallinan Appointed Chief Commercial Officer of Q'Apel Medical. Hallinan will lead the company’s global sales and marketing organization, oversee Q’Apel’s commercial strategy and drive revenue growth across Q’Apel’s expanding product portfolio. More at https://lnkd.in/eQwfCJwd

10/31/24: Bright Uro Announces Oversubscribed $32M Series A Funding Round - Derek Herrera, founder and CEO of Bright Uro. "With this funding, we are well-resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues." Full scoop at https://lnkd.in/e2nSvh6q